Lv1
40 积分 2025-11-18 加入
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, openlabel, crossover, non-inferiority trial
3个月前
已完结
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial
3个月前
已完结
Risk of Psychiatric Adverse Events Among Montelukast Users
6个月前
已完结
Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023
7个月前
已完结
Ocular Adverse Events With Semaglutide
7个月前
已完结
Ocular Adverse Events With Semaglutide
7个月前
已完结
GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity
7个月前
已完结
Dulaglutide as a Demethylating Agent to Improve the Outcome of Breast Cancer
7个月前
已关闭
皖公网安备34019202002308
